Our Member Services Representatives are unavailable Friday, April 10, due to the holiday.

 

CORONAVIRUS (COVID-19)

Resources on COVID-19 and how BCBSND is responding to help protect all North Dakotans

Adoptive Immunotherapy

Effective Date: April 01, 2019
Revised Date: April 27, 2019

Description

The spontaneous regression of certain cancers (eg, renal cell carcinoma, melanoma) supports the idea that a patient's immune system can delay tumor progression and, on rare occasions, can eliminate tumors altogether. These observations have led to research into various immunologic therapies designed to stimulate a patient's own immune system. Adoptive immunotherapy is a method of activating lymphocytes and/or other types of cells for the treatment of cancer and other diseases. Cells are removed from the patient, processed for some period of time, and then infused back into the patient.

Criteria

Coverage is subject to the specific terms of the member’s benefit plan.

Federal Employee Program members (FEP) should check with their Retail Pharmacy Program to determine if prior approval is required by calling the Retail Pharmacy Program at 1-800-624-5060 (TTY: 1-800-624-5077). FEP members can also obtain the list through the www.fepblue.org website.

Tisagenlecleucel (Kymriah) intravenous infusion is considered medically necessary for relapseda or refractoryb patients if they meet all of the following criteria:

  • Confirmed diagnosis of CD19-positive B-cell acute lymphoblastic leukemia with morphologic bone marrow tumor involvement (≥5% lymphoblasts)
  • Are up to 25 years old at the time of infusion
  • Have not received prior treatment with tisagenlecleucel or any other gene therapy or are being considered for treatment with any other gene therapy
  • Have adequate organ function with no significant deterioration in organ function expected within 4 weeks after apheresis
  • Do not have any of the following:
    • Burkitt lymphoma
    • Active hepatitis B, C, or any uncontrolled infection
    • Grade 2 to 4 graft-versus-host disease
    • Concomitant genetic syndrome with the exception of Down syndrome
    • Received allogeneic cellular therapy, such as donor lymphocyte infusion, within 6 weeks prior to tisagenlecleucel infusion
    • Patient has active central nervous system 3 acute lymphoblastic leukemia (ie, white blood cell count ≥5 cells/μL in cerebrospinal fluid with presence of lymphoblasts).

Relapsed disease describes the reappearance of leukemia cells in the bone marrow or peripheral blood after the attainment of a complete remission with chemotherapy and/or allogeneic cell transplant.

Refractory (resistant) disease is defined as those patients who fail to obtain complete response with induction therapy, ie, failure to eradicate all detectable leukemia cells (<5% blasts) from the bone marrow and blood with subsequent restoration of normal hematopoiesis (>25% marrow cellularity and normal peripheral blood counts).

Axicabtagene ciloleucel (Yescarta) or tisagenlecleucel (Kymriah) intravenous (except as indicateda) infusion is considered medically necessary for relapsed or refractoryb patients if they meet all of the following criteria:

  • Are adults (age ≥18) at the time of infusion
  • Histologically confirmed diagnosis of diffuse large B-cell lymphoma, not otherwise specified; or primary mediastinal large B-cell lymphomaa or high-grade B-cell lymphoma or diffuse large B-cell lymphoma arising from follicular lymphoma.
  • Received adequate prior therapy including all of the following
    • Anti-CD20 monoclonal antibody for CD20-positive tumor
    • Anthracycline-containing chemotherapy regimen
    • For subjects with transformed follicular lymphoma, prior chemotherapy for follicular lymphoma and subsequently have chemorefractory disease after transformation to diffuse large B-cell lymphoma
  • Have adequate organ and bone marrow function as determined by the treating oncologist/hematologist
  • Have not received prior CD19-directed CAR T-cell therapy treatment or any other gene therapy or are being considered for treatment with any other gene therapy.

AND

  • do not have primary central nervous system lymphoma.

Tisagenlecleucel intravenous infusion is considered investigational for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma.

Relapsed or refractory disease is defined as progression after 2 or more lines of systemic therapy (which may or may not include therapy supported by autologous cell transplant).

Other applications of adoptive immunotherapy are considered investigational.

Policy Guidelines

Autologous lymphocytes used as part of adoptive immunotherapy may be harvested in a pheresis procedure or may be isolated from resected tumor tissue.

The recommended dosage of tisagenlecleucel for patients with B-cell acute lymphoblastic leukemia who are 50 kg or less is 0.2 to 5.0×10chimeric antigen receptor-positive viable T cells per kilogram of body weight intravenously; for patients above 50 kg, dose is 0.1 to 2.5×10total chimeric antigen receptor-positive viable T cells (non-weight-based) intravenously.

The recommended target dose of tisagenlecleucel for patients with large B-cell lymphoma is 0.6 to 6.0 ×10chimeric antigen receptor-positive viable T cells intravenously.

The recommended target dose of axicabtagene ciloleucel for patients with large B-cell lymphoma is 2×10CAR-positive viable T cells per kg body weight, with a maximum of 2×10chimeric antigen receptor- positive viable T cells intravenously.

Central nervous system (CNS) disease for B-cell acute lymphoblastic leukemia is defined by the following groups:

  • CNS 1: Absence of blasts on cerebrospinal fluid cytospin preparation, regardless of the white blood cell (WBC) count
  • CNS 2: WBC count of less than 5/mL and blasts on cytospin findings
  • CNS 3: WBC count of 5/mL or more and blasts on cytospin findings and/or clinical signs of CNS leukemia (eg, facial nerve palsy, brain/eye involvement, hypothalamic syndrome)

Tisagenlecleucel and axicabtagene ciloleucel have black box warnings because of the risks of cytokine release syndrome and neurologic toxicities that include fatal or life-threatening reactions. They should not be administered to patients with active infection or inflammatory disorders. It is recommended that severe or life-threatening cytokine release syndrome be treated with tocilizumab. Patients should be monitored for neurologic events after treatment.

Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) are available only through a restricted program under a risk evaluation and mitigation strategy (REMS) called the Kymriah REMS and Yescarta REMS, respectively. The requirement for the REMS components are as follows:

  • Health care facilities that dispense and administer tisagenlecleucel or axicabtagene ciloleucel must be enrolled and comply with the REMS requirements.
  • Certified health care facilities must have onsite, immediate access to tocilizumab, and ensure that a minimum of 2 doses of tocilizumab are available for each patient for administration within 2 hours after tisagenlecleucel or axicabtagene ciloleucel infusion, if needed for treatment of cytokine release syndrome.
  • Certified health care facilities must ensure that health care providers who prescribe, dispense, or administer tisagenlecleucel or axicabtagene ciloleucel are trained to manage cytokine release syndrome and neurologic toxicities.

Procedure Codes

0537T 0538T 0539T 0540T 36511 Q2040 Q2041 S2107

NOTE: In addition to the above criteria, product specific dosage and/or frequency limits may apply in accordance with the U.S. Food and Drug Administration (FDA)-approved product prescribing information, national compendia, Centers for Medicare and Medicaid Services (CMS) and other peer reviewed resources or evidence-based guidelines. Blue Cross Blue Shield of North Dakota may deny, in full or in part, reimbursement for utilization that does not fall within the applicable dosage and/or frequency limits.

Links

  1. Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. Jul 13 2017;3(7):e170580. PMID 28494052
  2. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. Oct 15 2015;373(16):1541-1552. PMID 26465987
  3. Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. Jun 25 2015;125(26):4017-4023. PMID 25999455
  4. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. Feb 10 2011;29(5):551-565. PMID 21220611
  5. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified shortcourse multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. May 10 2010;28(14):2339-2347. PMID 20385996
  6. Bajwa R, Schechter T, Soni S, et al. Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplant. May 2013;48(5):661-665. PMID 23128573
  7. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. Apr 20 2006;24(12):1917-1923. PMID 16622268
  8. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. Dec 20 2016;34(36):4381-4389. PMID 27998223
  9. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. May 19 2016;127(20):2375-2390. PMID 26980727
  10. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. Sep 12 2016;66(6):443-459. PMID 27618563
  11. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498-505. PMID 22160081
  12. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. Sep 30 1993;329(14):987-994. PMID 8141877
  13. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (RIPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. Mar 01 2007;109(5):1857-1861. PMID 17105812
  14. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. Oct 19 2017;130(16):1800- 1808. PMID 28774879
  15. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. Feb 2011;137(2):305-310. PMID 20407789
  16. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. Apr 2008;8(4):299-308. PMID 18354418
  17. Novartis Pharmaceuticals. Prescribing Label: Kymriah™ (tisagenlecleucel) suspension for intravenous infusion. 2018; https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kymriah.pdf. Accessed June 19, 2018.
  18. Kite Pharma Inc. Prescribing Label: Yescarta™ (axicabtagene ciloleucel) suspension for intravenous infusion. 2017; https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/Approv edProducts/UCM581226.pdf. Accessed June 25, 2018.
  19. Tang X, Liu T, Zang X, et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS One. May 2013;8(5):e62847. PMID 23667530
  20. Xie F, Zhang X, Li H, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. Aug 2012;7(8):e42879. PMID 22916174
  21. Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract. Jan 2012;66(1):21-27. PMID 22171902
  22. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. Mar 10 2014;32(8):798-808. PMID 24344220
  23. Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. Jan 2014;22(1):132-139. PMID 24297049
  24. Ohtani T, Yamada Y, Furuhashi A, et al. Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers. Int J Oncol. Nov 2014;45(5):2051-2057. PMID 25120101
  25. Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. Jul 1 2014;74(13):3466- 3476. PMID 24795429
  26. Li JJ, Gu MF, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. Feb-Mar 2012;35(2):189-195. PMID 22306907
  27. Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. Mar 15 2012;18(6):1751- 1759. PMID 22275504
  28. Zhang Y, Wang J, Wang Y, et al. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clin Dev Immunol. Jan 2013;2013:195691. PMID 24382970
  29. Zhao X, Zhang Z, Li H, et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett. Jul 1 2015;362(2):192-198. PMID 25843292
  30. Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. Dec 2012;61(12):2251-2259. PMID 22674056
  31. Wang X, Tang S, Cui X, et al. Cytokine-induced killer cell/dendritic cell-cytokineinduced killer cell immunotherapy for the postoperative treatment of gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore). Sep 2018;97(36):e12230. PMID 30200148
  32. Zhao H, Wang Y, Yu J, et al. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. Clin Colorectal Cancer. Sep 2016;15(3):228-235. PMID 27052743
  33. Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A, et al. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. J Cell Physiol. Oct 28 2018. PMID 30370522
  34. Cai XR, Li X, Lin JX, et al. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. Oncotarget. May 09 2017;8(19):31318-31328. PMID 28412743
  35. Yu X, Zhao H, Liu L, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. Feb 2014;34(2):194-203. PMID 24337625
  36. Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. Jan 15 2014;134(2):342-351. PMID 23825037
  37. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokineinduced killer cells for hepatocellular carcinoma. Gastroenterology. Jun 2015;148(7):1383-1391 e1386. PMID 25747273
  38. Wang M, Cao JX, Pan JH, et al. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PLoS One. Nov 2014;9(11):e112662. PMID 25412106
  39. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. Nov 10 2008;26(32):5233-5239. PMID 18809613
  40. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. Jul 01 2011;17(13):4550-4557. PMID 21498393
  41. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. Nov 2002;51(10):539-546. PMID 12384805
  42. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. Aug 1999;17(8):2521-2529. PMID 10561318
  43. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. Mar 01 2002;99(5):1517-1526. PMID 11861263
  44. Lacy MQ, Wettstein P, Gastineau DA, et al. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma [abstract]. Blood. 1999;94(10 supp part 1):122a. PMID
  45. Motta MR, Castellani S, Rizzi S, et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol. Apr 2003;121(2):240-250. PMID 12694245
  46. Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. Dec 15 2000;89(12):2646-2654. PMID 11135227
  47. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. Oct 15 2003;21(20):3826-3835. PMID 14551301
  48. Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori. MayJun 2012;98(3):314-319. PMID 22825506
  49. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. Jan 2013;62(1):65-73. PMID 22744010
  50. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. May 01 2003;63(9):2127-2133. PMID 12727829
  51. Santin AD, Bellone S, Palmieri M, et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol. May 2003;89(2):271-280. PMID 12713991
  52. Tanyi JL, Chu CS. Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. Immunotherapy. Oct 2012;4(10):995-1009. PMID 23148752
  53. Bregy A, Wong TM, Shah AH, et al. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev. Dec 2013;39(8):891-907. PMID 23790634
  54. Liau LM, Ashkan K, Tran DD, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. May 29 2018;16(1):142. PMID 29843811
  55. Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol. Oct 2014;22(2):451-464. PMID 25073120
  56. Bachleitner-Hofmann T, Friedl J, Hassler M, et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep. Jun 2009;21(6):1585-1592. PMID 19424640
  57. Hirooka Y, Itoh A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas. Apr 2009;38(3):e69-74. PMID 19276867
  58. Ngo MC, Rooney CM, Howard JM, et al. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. Apr 15 2011;20(R1):R93-99. PMID 21415041
  59. Ochi T, Fujiwara H, Yasukawa M. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer. Expert Opin Biol Ther. Jun 2011;11(6):699-713. PMID 21413911
  60. Humphries C. Adoptive cell therapy: Honing that killer instinct. Nature. Dec 19 2013;504(7480):S13-15. PMID 24352359
  61. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. Jul 16 2009;114(3):535-546. PMID 19451549
  62. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. Oct 01 2007;110(7):2620-2630. PMID 17507664
  63. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. Sep 15 2008;112(6):2261-2271. PMID 18509084
  64. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. Dec 2004;114(12):1774-1781. PMID 15599402
  65. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. Nov 2008;14(11):1264-1270. PMID 18978797
  66. Food and Drug Administration (FDA). FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting (BLA 125646,Tisagenlecleucel). n.d.; https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Onc ologicDrugsAdvisoryCommittee/UCM566166.pdf. Accessed June 25, 2018.
  67. Food and Drug Administration (FDA). FDA Presentations for the July 12, 2017 Meeting of the Oncologic Drugs Advisory Committee. 2017; https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Onc ologicDrugsAdvisoryCommittee/UCM567383.pdf. Accessed June 25, 2018.
  68. Novartis Pharmaceuticals. Briefing Document: Oncologic Drugs Advisory Committee Meeting: Tisagenlecleucel (CTL019) (BLA 125646). 2017; https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Onc ologicDrugsAdvisoryCommittee/UCM566168.pdf. Accessed June 25, 2018.
  69. Novartis Pharmaceuticals. Presentations for the July 12, 2017 Meeting of the Oncologic Drugs Advisory Committee: CTL019 (tisagenlecleucel). 2017; https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Onc ologicDrugsAdvisoryCommittee/UCM567385.pdf. Accessed July 24, 2017.
  70. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. Sep 20 2014;32(27):3059-3068. PMID 25113753
  71. AMCP Formulary Dossier Version 4: Kymriah (Tisagenlecleucel[CTL019]): Version Date: May 2018. Accessed June 27, 2018.
  72. Food and Drug Administration (FDA). Summary Basis for Regulatory Action for Yescarta (BLA 125643). 2017; https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/Approv edProducts/UCM584335.pdf. Accessed June 25, 2018.
  73. Center for Biologics Evaluation and Research, Food and Drug Administration. Yescarta BLA Approval Letter. 2017; https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/Approv edProducts/UCM581259.pdf. Accessed June 25, 2018.
  74. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: bladder cancer. Version 4.2018.http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed June 19, 2018.
  75. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers. Version 1.2018.http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed June 19, 2018.
  76. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: head and neck cancers. Version 1.2018.http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed June 19, 2018.
  77. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 2.2018.http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed June 19, 2018.
  78. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: kidney cancer. Version 4.2018.https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed June 19, 2018.
  79. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 1.2018.http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed June 19, 2018.
  80. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: gastric cancer.Version 2.2018.http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed June 19, 2018.
  81. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: thyroid carcinoma. Version 1.2018.http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed June 19, 2018.
  82. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: melanoma. Version 2.2018.https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed June 19, 2018.
  83. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. Version 3.2018.http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed June 19, 2018.
  84. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 4.2018.http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 19, 2018.
  85. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia. Version 1.2018.https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed June 19, 2018.
  86. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: B-Cell lymphomas. Version 4.2018.https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed June 19, 2018.